RecallRadar

FDA Drug recall D-0037-2026

Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limi…

On 2025-10-29 the FDA classified a Class II recall of Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limi… by Graviti Pharmaceuticals Private, citing failed Tablet/Capsule Specifications.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0037-2026
ClassificationClass II
Statusongoing
Initiated2025-09-15
Published2025-10-29
Last updated2026-09-13 11:52 UTC
CompanyGraviti Pharmaceuticals Private
DistributionUS

Product

Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg, 30-count bottles, Rx Only, Mfd. by: Graviti Pharmaceuticals Private Limited, Sangareddy, Telangana, India, Dist. by: Rising Phar, NDC 16571-863-03.

Reason

Failed Tablet/Capsule Specifications

Identifiers

ndc16571-862-03
ndc16571-862-09
ndc16571-862-50
ndc16571-862-10
ndc16571-862-12
ndc16571-863-03
ndc16571-863-09
ndc16571-863-50
ndc16571-863-10
code_infoBatch # BPB124341A, Exp date: 10/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0037-2026%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.